Skip to main content

Tang Kevin C's Form 4 filing

Odonate Therapeutics, Inc. (ODT) · filed Nov 19, 2021

Accession no.
0001209191-21-065826
Filed
Nov 19, 2021, 4:38 PM ET
Trade date
Nov 17-19, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 8 non-derivative transactions. Open-market sales total $5.73M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Tang Kevin CCIK 0001178579Director, Officer (Chief Executive Officer), 10% Owner
Hearne Michael SCIK 0001759910Officer (Chief Financial Officer)
Tang Capital Partners LPCIK 000119193510% Owner
Tang Capital Management LLCCIK 000123262110% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 17, 2021Common StockSSaleDisposed−468,849$2.66F1−$1,246,341.315,045,717Indirect
Nov 17, 2021Common StockSSaleDisposed−31,151$1.99F3−$62,118.2115,014,566Indirect
Nov 17, 2021Common StockSSaleDisposed−500,000$2.02F4−$1,008,05014,514,566Indirect
Nov 17, 2021Common StockSSaleDisposed−287,577$2.20F5−$632,238.0314,226,989Indirect
Nov 18, 2021Common StockSSaleDisposed−212,423$1.97F6−$418,643.2514,014,566Indirect
Nov 18, 2021Common StockSSaleDisposed−500,000$1.88F7−$940,60013,514,566Indirect
Nov 18, 2021Common StockSSaleDisposed−381,842$1.89F8−$722,635.9913,132,724Indirect
Nov 19, 2021Common StockSSaleDisposed−365,289$1.92F9−$699,930.2512,767,435Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.01 to $3.01. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 3 through 9 herein.

Referenced by the price of 1 transaction in Table I.

F3

The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.99 to $2.005.

Referenced by the price of 1 transaction in Table I.

F4

The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.95 to $2.07.

Referenced by the price of 1 transaction in Table I.

F5

The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.33.

Referenced by the price of 1 transaction in Table I.

F6

The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.91 to $2.16.

Referenced by the price of 1 transaction in Table I.

F7

The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.99.

Referenced by the price of 1 transaction in Table I.

F8

The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $2.001.

Referenced by the price of 1 transaction in Table I.

F9

The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.985.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)